OBJECTIVES: To evaluate the financial consequences of sertindole reimbursement for the Polish National Health Fund (NHF) budget. METHODS: Budget impact analysis was performed in a 3-year time horizon from two perspectives of NHF and a patient. Costs of oral antipsychotic drugs and EKG test of patients treated with sertindole were included. Two future scenarios were estimated: 1) with reimbursement of sertindole, and 2) without sertindole reimbursement. Target population was estimated using Polish epidemiological and statistical data, and a systematic review (proportion of patients treated with antipsychotic drugs who withdrew because of adverse events). Current and predicted market shares were assessed on the basis of present sales level data. RESULTS: In the first scenario, NHF expenditures on atypical antipsychotic drugs will increase by: 13 mln PLN in 2010, 20 mln PLN in 2011 and 26 mln PLN in 2012. In the second scenario of no sertindole reimbursement NHF expenditures on atypical antipsychotic drugs will increase by: 11 mln PLN in 2010, 18 mln PLNin 2011 and 23 mln PLN in 2012. From patient’s perspective, expenditures will increase in 2010 – 2012 by 0,9 mln PLN 1.3 mln PLN and 1.7 mln respectively in scenario with sertindole reimbursement, while in a second scenario costs will increase in 2010 - 2012 by 1.1 mln PLN, 1.6 mln PLN and 2,0 mln PLN respectively. The 2009 weighted average exchange rate of Polish National Bank was € 1 = PLN 4.3273. CONCLUSIONS: Reimbursement of sertindole would result in a minor increase in Polish NHF expenditures. Simultaneously, it would enlarge the scope of accessible therapies for patients intolerant to at least one other antipsychotic agent.